(Q37995012)

26 August 2017

title

Role of mesenchymal stem cell therapy in Crohn's disease (English)

1 reference

26 August 2017

0 references

mesenchymal stem cell

1 reference

Jignesh Dalal

1

1 reference

26 August 2017

Kimberly Gandy

series ordinal

2

1 reference

26 August 2017

Jos Domen

series ordinal

3

1 reference

26 August 2017

language of work or name

English

0 references

publication date

8 February 2012

1 reference

26 August 2017

1 reference

26 August 2017

volume

71

1 reference

26 August 2017

issue

4 Pt 2

1 reference

26 August 2017

page(s)

445-451

1 reference

Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

The fundamental basis of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

Review article: stem cell therapies for inflammatory bowel disease - efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

Infliximab therapy in pediatric Crohn's disease: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

Epidemiology and the natural course of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

Marrow stromal cells as stem cells for nonhematopoietic tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

Mesenchymal stem cells promote engraftment of human umbilical cord blood-derived CD34(+) cells in NOD/SCID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

Direct imaging of immune rejection and memory induction by allogeneic mesenchymal stromal cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

Sarcoma derived from cultured mesenchymal stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

Family and twin studies in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

The immunopathogenesis of Crohn's disease: a three-stage model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

Anti-interleukin-12 antibody for active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

Sargramostim for active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

Microbes in gastrointestinal health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

Infectious gastroenteritis and risk of developing inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

Pathobionts of the gastrointestinal microbiota and inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

Colitis-associated colorectal cancer driven by T-bet deficiency in dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

Enterobacteriaceae act in concert with the gut microbiota to induce spontaneous and maternally transmitted colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

Lactobacillus casei downregulates commensals' inflammatory signals in Crohn's disease mucosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

Bacteroides vulgatus protects against Escherichia coli-induced colitis in gnotobiotic interleukin-2-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

Pretreatment with interferon-γ enhances the therapeutic activity of mesenchymal stromal cells in animal models of colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

Targeting improves MSC treatment of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

Complete remission of Crohn's disease after high-dose cyclophosphamide and autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

Crohn's disease recurrence in a small bowel transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

Mouse bone marrow-derived mesenchymal stromal cells turn activated macrophages into a regulatory-like profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

A Phase I Clinical Trial of the Treatment of Crohn's Fistula by Adipose Mesenchymal Stem Cell Transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

Concise review: mesenchymal tumors: when stem cells go mad.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

Lactic acid bacteria inhibit proinflammatory cytokine expression and bacterial glycosaminoglycan degradation activity in dextran sulfate sodium-induced colitic mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

Toll-Like Receptors 3 and 4 Are Expressed by Human Bone Marrow-Derived Mesenchymal Stem Cells and Can Inhibit Their T-Cell Modulatory Activity by Impairing Notch Signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

Improvement of inflammatory bowel disease after allogeneic stem-cell transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

Course of Crohn's disease after allogeneic marrow transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

Autologous hematopoietic stem cell transplantation for autoimmune diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

PBSC autotransplant for inflammatory bowel disease (IBD): a case of ulcerative colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

Mesenchymal stem cell therapy of Crohn's disease: are the far-away hills getting closer?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

Mesenchymal stromal cell function is not affected by drugs used in the treatment of inflammatory bowel disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.56

31 March 2020

Identifiers

DOI

10.1038/PR.2011.56

1 reference

26 August 2017

1 reference